aTYR PHARMA INC
ATYR· Nasdaq
ATYRaTYR PHARMA INC
Filed Mar 14, 2023 · 10-K · 73 days after period end · 0000950170-23-007873
derived · Computed from the longer spans the company filed.
| Metric | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures | Q4 2019 |
|---|---|---|---|---|
| Revenue | — | — | $2.05M | — |
| Net Income | -$7.52M | -$8.56M | -$4.93M | -$5.97M |
| EPS Diluted | — | — | — |
aTYR PHARMA INC · CIK 1339970 · Engraved from SEC EDGAR
| -$1.54 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2022 · filed Mar 14, 2023 · 73 d after period end
